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Abstract 
Nikia Smith 
Environmental Epigenomics: Altered DNA Methylation Patterns in Humans Exposed to 
Inorganic Arsenic 
(Under the Direction of Dr. Rebecca Fry) 
Inorganic arsenic is a contaminant currently poisoning the drinking water supplies of many 
countries around the world.  High doses of inorganic arsenic can lead to arsenic poisoning, 
which is characterized by skin lesions and skin cancer.  It is thought that arsenic may affect 
gene regulation via epigenetic modes of action such as DNA methylation rather than 
mutating the DNA sequence of genes.    In this study we compared the methylation profiles 
of 16 individuals from an arsenic endemic region of Mexico. These individuals had varying 
levels of exposure to arsenic and half displayed signs of arsenicosis. Comparative analyses 
showed that there were significant differences in the methylation levels of cancer-associated 
genes between arsenic-exposed and unexposed individuals. These data demonstrate the 
significant effects of arsenic on the epigenome and highlight the continued need for 
monitoring of exposure and subsequent health consequences of populations around the globe.   
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1 Introduction 
1.1 Inorganic Arsenic Exposure: Sources and Health Effects 
Arsenic is a worldwide contaminant and public health concern, affecting the drinking 
water supplies of millions around the world (Nordstrom, 2002; Smith et al. 2000).  The 
Environmental Protection Agency (EPA) and World Health Organization’s (WHO) inorganic 
arsenic drinking water standard is reported as 10 ppb.  Countries affected by arsenic 
exposures higher than standard levels include the United States, Argentina, Chile, Taiwan, 
China, India, Bangladesh, and Mexico.  In particular, Bangladesh has a major problem with 
arsenic-contaminated ground water.  The World Health Organization reported that 35-77 
million of the 125 million people in Bangladesh are possibly exposed to arsenic 
contaminated drinking water (WHO, 2001). Arsenic-contaminated drinking water originates 
from mining operations and natural leaching from the earth into drinking water (Nordstrom, 
2002).  Arsenic contamination in ground water became a concern to residents of Bangladesh 
when UNICEF dug ground wells to make pathogen-free water available to the residents of 
Bangladesh (Smith et al., 2000).  This act to reduce pathogenic disease in Bangladesh led to 
the exposure of millions to high-dose arsenic and their subsequent development of 
arsenicosis.  
Exposure to inorganic arsenic has been linked to various diseases, both cancerous and 
non-cancerous.  Examples of non-cancerous disease endpoints associated with exposure to 
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inorganic arsenic exposure are cardiovascular diseases (Wang et al., 2007), type 2 diabetes 
(Navas-Acien et al., 2008), and skin lesions (Ahsan, et al., 2006).  In addition, maternal 
exposure to arsenic above the standard level has been suggested to lead to fetal loss and 
infant death in a dose-response manner (Rahman et al. 2007).  It is suggested that cancerous 
diseases associated with high-dose arsenic exposures include bladder, lung, kidney, and skin 
cancers (Chen et al., 1992; Chen and Ahsan, 2004). 
 
1.2 Arsenic Exposure Effects on DNA Methylation 
The biological mechanism behind cancer development, as a result of arsenic 
exposure, remains largely elusive.  Arsenic is weakly mutagenic, and therefore leads to the 
notion that arsenic exposure can initiate the transformation of normal, healthy cells into 
tumor cells through a mechanism that does not involve mutagenesis. Recent studies have 
shown that exposure to inorganic arsenic may lead to disease through DNA methylation 
interference.  For example, in rodent models, exposure to arsenic modulates global gene 
methylation and gene specific methylation (Xie, et al., 2007; Zhao et al., 1997). It has been 
suggested that exposure of human cells to arsenic modifies DNA methylation patterns of 
specific genes (Benbrahim-Tallaa, et al., 2005; Mass & Wang, 1997; Zhong & Mass, 2001).  
Alterations of DNA methylation in the promoter regions of tumor-suppressor genes (p53 and 
p16) were observed in humans exposed to arsenic in Bangladesh (Chanda, et al., 2006). 
Recently, global genomic hypermethylation has been observed in individuals exposed to 
arsenic (Majumdar et al., 2009).  Finally, it has been suggested that prenatal exposure to 
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Figure 1.The scheme of arsenic 
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arsenic affects gene expression possibly through DNA methylation pattern changes in both 
rodents and humans (Fry et al., 2007; Xie et al., 2007). 
 
Normally, DNA methylation mechanisms are thought to control gene expression and 
development (Meehan, 2003).  This mechanism of gene control is especially important in 
early embryonic development when cells develop into organ specific cells (Meehan, 2003).  
The process of DNA methylation involves the transfer of a methyl group to the 5
th
 carbon of 
the nucleotide base cytosine at cytosine-phosphate-guanine (CpG) sites.  CpG sites can be 
located throughout the genome, but a heavy concentration of CpG sites are usually found in 
the regulatory regions of genes.  These sites are usually unmethylated, but have been shown 
to be hypermethylated in the tumor cells of various cancers.  DNA methylation is maintained 
by the enzyme DNA methylation transferase (DNMT), which is responsible for maintaining 
DNA methylation levels across the genome (Novik and Piepenbrock, 2002).   One theory of 
how arsenic affects DNA methylation considers that the mechanism that controls arsenic 
metabolism and DNA methylation share the same co-factor, S-adenosylmethionine (SAM) 
(Zhao, et al., 1997).  SAM is a cofactor that is involved in the transfer of methyl groups to 
the 5
th
 carbon of cytosine at CpG sites.  It is thought 
that inorganic arsenic dysregulates SAM and DNA 
methyltransferase, thereby causing aberrant DNA 
methylation patterns (Zhao et al. 1997; Reichard et al. 
2007). 
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In the past, the general perception of arsenic-induced carcinogenesis was that arsenite 
was the most likely cause of carcinogenesis, and that methylation of arsenic species was a 
detoxifying pathway (Kitchin, 2001).  In recent years, it has become apparent that the 
generation of methylated metabolites of inorganic arsenic is not necessarily a detoxification 
process and that the trivalent methylated intermediates (MMA
III
 and DMA
III
) formed in this 
pathway may be more reactive and toxic than inorganic arsenic (Styblo et al. 2000; Mass et 
al. 2001; Chen et al. 2003; Drobna et al. 2003; Thomas et al. 2007).  This metabolic 
conversion of inorganic arsenic into methylated products is a multistep process (Figure 1). 
 
Considerable interest exists in understanding the biological effects upon exposure to 
the trivalent arsenicals methylarsonous acid (MMA
III
) and dimethylarsinous acid (DMA
III
).  
MMA
III
 in particular may play a critical role in carcinogenesis as humans excrete much more 
MMA than any other species (Vahter, 1994).  MMA
III
 may, therefore, be linked to the 
heightened sensitivity of humans to arsenic-induced carcinogenesis. Indeed, previous studies 
in Mexico and Taiwan reported increased risks of skin lesions in individuals with higher 
urinary concentrations of MMA
III
 or with higher MMA
III
/DMA
III
 ratios in urine (Valenzuela 
et al., 2005; Yu et al., 2000). In addition, it is clear that differences in inter-individual 
metabolism of arsenic may influence ultimate susceptibility to arsenic-induced disease 
(Hernandez and Marcos, 2008).  
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Figure 2: The map of Mexico. Outlined is the 
area where concentrations in drinking water 
often exceed 50 ppb Arsenic (i.e., 50 μg As/l). 
Zimapan
Mexic o
Lagunera
1.3 Study Objectives and Overview 
The objective of this study was to determine the differences in the methylation 
patterns in the epigenome of individuals, with similar demographic backgrounds, who either 
hada skin disease phenotype or a normal skin phenotype.  We compared the methylation 
profiles of 16 individuals from an arsenic endemic region of Mexico. These individuals had 
varying levels of exposure to arsenic and some displayed signs of arsenicosis. Two state-of-
the-art technologies were used to examine the DNA methylation profiles of these individuals, 
including reduced representation bisulfite sequencing (RRBS) and methylated CpG island 
recovery assay (MIRA). These analyses were used to assess differential methylation across 
the genomes of the study subjects at more than 1 million CpG sites. Comparative network 
analyses were used to show significant differences in the methylation levels of cancer-
associated genes, such as NF-κB and p53,between individuals with skin disease and those 
without.   
 
2  Materials and Methods 
2.1 Study Region and Study Population 
The city of Zimapan in the Hidalgo 
region of Mexico (see Figure 2) was chosen 
as a study site because of its history with 
regions that are exposed to high levels of 
arsenic left from mining and other industries 
that occupied the area.  The levels of inorganic arsenic in the drinking water of Zimapan 
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range from 8-1,100 ppb.  Zimapan is part of a large geological area where high 
concentrations of inorganic arsenic (up to 1.1 ppm) have consistently been found in drinking 
water supplies. Approximately 2 million people reside in this area. In the Zimapanregion 
alone, more than 400,000 people drink water with arsenic levels higher than 25 ppb. A high 
prevalence of a skin disease typical of the chronic inorganic arsenic poisoning has been 
reported among the local residents.  
 
In 2006, 250 Zimapan and Lagunera residents (adults and children) were recruited to 
participate in a US Environmental Protection Agency (EPA)-funded study examining 
relationships between the inorganic arsenic exposure, inorganic arsenic metabolism, and 
biomarkers of adverse health effects (EPA study No. 832735; PI: Styblo; study period: 2/06-
2/09).  The endpoints examined in the EPA study included: the concentration of arsenic in 
drinking water in the participating households, the number and types of skin lesions, and the 
concentrations of total arsenic and of inorganic metabolites in urine. Preliminary results 
showed that the concentration of total arsenic in urine of the study subjects ranged from 0.5 
to 459 ppb. The majority of the collected urine samples contained all known As
V
- and As
III
-
containing metabolites of inorganic arsenic.  
  
          Evaluation of skin disease was completed in the Zimapan region by Dr. Gonzalo G. 
Garcia Vargas of Juarez University located in Durango State Mexico. The skin lesions, 
including skin cancer, were found in 27% of the study subjects.  We selected 16 from the 250 
original samples to do our analyses.  We limited our study to 16 individuals due to cost 
constraints.  The 16 study participants chosen for our analyses were all women.  Many of the 
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women lived a majority of their lives in the village where their blood and urine specimens 
were collected.  The average length of time that the women lived in the area was 27.8 ± 12.4 
years. The mean age of women in this study was 36 years andranged from 12 to 59. 
For the first analysis, we selected 2 of our 16 samples for deep sequencing.  Based on 
cost constraints and lack of sufficient DNA quantity for deep sequencing, we chose to 
process all 16 samples using the RRBS technology.   
 
2.2 Reduced Representation Bisulphite Sequencing (RRBS) 
The methods used here are a modification of the methods from Meissner et al. (2008).  
Whole blood was drawn from arsenic exposed and unexposed individuals who reside in the 
Hidalgo region of Mexico.  Unexposed individuals were those individuals who were exposed 
to inorganic arsenic levels lower than the regulatory limit of 10 ppb in their drinking water.  
DNA was extracted from the whole blood of the study participants using a DNeasy blood and 
tissue kit (Qiagen, Valencia CA).  DNA was stored at -80ºC until further analysis could be 
completed.              
            We used RRBS to identify methylatedCpG sites across the genome. RRBS was 
performed by cutting genomic DNA with the methylation-insensitive restriction enzyme 
MspI, which cuts at the first 5’ C of CCGG sites.  Fragments in the size range from 40-300 
bps were produced and DNA fragments in the range of 200 bp ± 25 bp were enriched.Once 
fragmented, the DNA fragments ends were repaired and filled in using adenylation.  
Universal adapters were added by ligation to the 3’ and 5’ end of each DNA fragment.  These 
fragments with adapters were denatured and bisulfite treated, which converts unmethylated 
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cytosines to uracil while methylated cytosines at CpG sites are protected from conversion.  
Fragments were then PCR amplified for 6 cycles and size selected for fragments between 30 
and 440 bp in length.  Once these fragments were identified, they were sequenced on a flow 
cell.  The adapters were hybridized to the surface of the flow cell, which has a dense lawn of 
oligos that hybridize to the universal adapters attached to the DNA fragments.  The 
fragments were then subjected to bridge amplification.  The resulting fragments were then 
sequenced using photochemical technology.  Each nucleotide added during the sequencing 
stage was fluorescently labeled, and as the nucleotide was incorporated into the strand, it 
released the fluorescent tag.  The colored fluorescent tags, released after incorporation,were 
read and captured as images, which were use to determine the sequence of nucleotides as 
they were added to the strand.   
 
2.3 MethylatedCpG Island Enrichment Assay (MIRA) 
Our laboratory developed a procedure to enrich methylation at a fraction of the cost 
of deep sequencing.   First DNA extracted from whole blood was sonicated to shear DNA 
into fragments.  We used MethylCollector™ Ultra (Active Motif, Carlsbad, CA) to pull 
down methylated fragments from the sheared DNA.   The DNA fragments were then bound 
to His-MBD2b/MBD3L1 protein complexes, which are attracted to methylatedCpG sites.  
The DNA/Protein complexes were then captured using nickel-coated magnetic beads (Active 
Motif, Carlsbad, CA).  A magnet was used to draw the magnetic beads to the side of the 
sample tube.  The magnetic beads were then washed three times to remove unmethylated 
DNA fragments.  Proteinase K was added to elution buffer to degrade the protein complexes, 
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thereby releasingmethylated DNA fragments.  The released Methylated fragments were 
purified for further processing.  Fragments were then subjected to two rounds of whole 
genome amplification (WGA) to amplify products to a sufficient quantity.  The amplified 
product was then fragmented and labeled.  Once labeled the amplified methylated fragments 
were loaded onto a Human Promoter 1.0R array (Affymetrix, Santa Carla, CA).  Data from 
the promoter arrays consisted of probe coordinates and the abundance signals of the enriched 
methylated fragments that bound to probes on the promoter array.  Finally, the coordinates 
obtained were mapped to CpG islands across the genome.  The abundance of methylated 
fragments across each CpG site was summed and then divided by the number of coordinates 
that mapped to the CpGisland to calculate average abundance of methylation per CpGisland.   
 
2.4 Statistical Analysis 
Promoter array data were analyzed using Partek Genomic Suite 6.4 software 
(PartekInc.,St. Louis, MO).  The Robust mult-array analysis (RMA) algorithm was used for 
probeset intensity analysis.  To compare differences in methylation between the skin disease 
group and the healthy group, analysis of variance (ANOVA) and multitest correction for P-
values in Partekwas implemented to identify significant differentially methylatedgenes 
between the exposed and control group.   
Specifically, this list of genes with significant differential methylationwas created 
using 0.05 false discovery rate (FDR) criterion as a standard cutoff.  FDR is the proportion of 
false positives among all positives.  Partek uses the q-value method to control the FDR. 
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The significant genes were sorted, based gene function, using Ingenuity pathway 
analysis (IPA) software (Ingenuity Systems, www.ingenuity.com).  In depth study of 
identified gene functions and the biological pathways associated with the identified gene set 
was restricted to those genes with functions identified as being associated with cancer 
development including differentiation, cell-to-cell communication, apoptosis, cell death, and 
tumorigenesis. 
Networks of molecules were generated from statistically significant differentially 
methylated genes, and analyzed using IPA.  Network eligible molecules were combined into 
networks that maximize the biological relationship of each molecule in the generated 
networks to all other molecules that they are associated with in IPA’s database.  The 
networks generated are scored according to the number of network eligible molecules they 
possess.  The higher the network score, the lower the probability of observing the generated 
network by random chance.  P-values generated from biological functions associated with 
specific networks in IPA are calculated using the right-tailed Fisher’s exact test. 
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Table 1. Skin phenotype identification of study population.  
Sample ID Skin Phenotype
1 No Disease
2 No Disease
3 Hyperkeratosis  
4 No Disease
5 No Disease
6 No Disease
7 Hyperkeratosis  
8 Hyperkeratosis
9 No Disease
10 Hyperkeratosis
11 No Disease
12 Hypopigmentation
13 No Disease
14 Hyperkeratosis and Horns Cutaneous
15 Basal Cell Carcinoma, Squamous Cell 
Carcinoma, Melanomas
16 Bowen’s Disease,  Keratosis, Squamous
Cell Carcinoma  
3 Results 
3.1 Reduced Representation Bisulfite Sequencing (RRBS) 
Skin disease is associated with modulation of the methylation status of genes in 
the NFκB pathway.  RRBS was used to identify the methylatedCpG sites across the 
genomes of individual 15, who had evidence of skin lesions, and control individual 13, who 
had no evidence of skin lesions (see Table 1).  Individual 13 was selected because there was 
sufficient DNA available in this sample to perform RRBS.   
RRBS implements the use of deep sequencing to generate multiple 50 base pair reads 
of Msp1 restriction fragments cut at the first C of each CCGG site across the genome.  This 
process is detailed in the material and methods section of this paper.  From deep sequencing 
of sample 13 a total of 4,596,109 reads were generated and 15,109 of those reads mapped to 
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Table 2. Common CpGsites between samples 13 (Control) and 15(Exposed) 
 Sample 13 
(Control) 
Sample 15 
(Exposed) 
Common between 13 
and 15 
Total CPG Sites  
(10 X coverage)  
1639873 1634645 1486309 
CpGsites within CpG 
Islands  
1024493 1035222 955267 
 
Common total CpG sites fall into CpG islands of 21,888 genes  
 
 
an MspI in silico digested reference genome.  For sample 15, total reads equaled 5,071,268 
and total mapped reads were 11,961 reads.   The aligned reads for each sample identified 1.6 
million methylated CpG sites with at least 10X coverage (see Table 2).   
 
Samples 13 and 15 had 1.4 million of these methylated CpG sites in common.  Close to 1 
million ofthese common sites fell into the CpG islands of 21,888 genes.  Average 
methylation was calculated across 21,888 CpG Islands for both samples.  Next, the average 
methylation of each CpG island across the genome of sample 15 (exposed) was divided by 
the average methylation across the CpG islands of sample 13 (control).  The average 
methylation levels across the control sample’s CpG islands were used as a baseline for 
determining methylation changes in the exposed sample.   The differences in average 
methylation levels between the control and the exposed sample were filtered for a four-fold 
or greater change.  From the 21,888 gene set, 791 genes showed a four-fold or greater 
decrease in average methylation in the exposed sample when compared to the control.  About 
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Figure 3. High-dose arsenic exposure is associated with 
modulation of the methylation status of genes in the 
NFκB pathway. 
p<10-43
321 genes displayed a four-fold or greater increase in average DNA methylation.  These 
results show that a total of 1112 genes were differentially methylated in high-dose arsenic-
exposed subject 15.    
 
The genes that were 
differentially methylated were 
analyzed for significant molecular 
interactions using the Ingenuity 
pathway analysis tool. The results 
from our network analysis 
displayed 6 hypermethylated 
genes and 26 hypomethylated 
genes associated with the NF-κB pathway (see Figure 3).   The molecular network was 
highly significant (p< 10
-43
) (see Figure 3).   
 
3.2 MethylatedCpG Island Enrichment Assay (MIRA) 
Arsenicosis is associated with an increase in DNA methylation in the promoter 
regions of genes.  We used MIRA to determine the abundance of methylated sites in the 
promoter regions of 14,363 genes.  The final step in the methyl enrichment process was to 
add methylation enriched DNA to the promoter array (as described in Materials and 
Methods).  The promoter array consisted of 4.6 million probes.  Our results show that the 
methylation enriched fragments pulled down from the DNA of our 16 samples (see Figure 1) 
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Figure 4. Arsenicosis is associated with higher methylation levels in the 
promoter regions of genes across the genome.  Red color indicates 
hypermethylation, blue color indicates hypomethylation, and gray color is the  
baselinemethylation level. 
 
 
each hybridized to 4,265,949 probes.  The methylation-enriched fragments identified by the 
promoter array probes, from each of our 16 samples, were mapped to 14,363 genes.  Next, 
we used a heat map to compare how different the average methylation across 14,363 genes of 
each sample was from the additional 15 samples (Figure 4).  The 16 samples were separated  
equally into two groups, an arsenicosis groupand a healthy group.  The abundance of 
methylated fragments for the two groups was compared using a student’s t-test (α=0.05).   
 
 
 
 
 
 
 
 
 
 
 
These results showed that arsenicosis was significantly associated with a higher 
abundance of methylated fragments across 14,000 genes as seen in Figure 4.   Next, the 
1
4
,3
6
3
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e
n
e
s
 
 15 
 
 
Figure 5. NFKB-associated network associated with Skin Disease.  An interactome 
was identified that displays genes associated with NF-κB (A) and p53 (B) that were 
differentially methylated between individuals with signs of arsenicosis and healthy 
individuals. 
 
 
14,000 gene set was analyzed to find the most significant differentially methylated genes 
between the skin disease group and the normal group.  We performed ANOVA with a 
multitest correction and a 1.3-fold change in methylation cutoff, which resulted in the 
identification of 183 genes that showed significant differences in methylation between the 
skin disease group and the normal group.   
Molecular interactome analysis shows differential methylation between the healthy 
study group and the arsenicosis group.  Investigation into significant biological 
interactions of differentially methylated genes between the skin disease group and control 
group of the study population was carried out using IPA mapping system.  The statistically 
significant gene set, with q values less than 0.05 and with fold changes of at least 1.3 
between the arsenicosis and healthy group, was analyzed for molecular interactions using 
156 of the 183 genes, which mapped to protein networks for analysis.  From the network 
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analysis, we discovered that 21 hypermethylated genes were associated with the NF-κB 
pathway (see Figure 5A).  There were 14 hypermethylated genes that were associated with 
p53 (see Figure 5B). 
Of the 125 mapped genes, 11 or 9% of these genes were significantly associated with 
cancer.  Of the 11 cancer-associated genes identified, 5 were enriched for tumorigenesis 
(p<0.0296) and 5 were enriched for transformation (p<0.0401).  The differentially 
methylated genes in our arsenicosis group were also associated with other arsenicosis-related 
diseases, such as cardiovascular disease (p<0.044), gastrointestinal disease (p<0.0296)   
Top associations of the geneset with molecular and cellular functions were also 
analyzed.  As many as 20% or 26 genes of the 126 mapped genes were found to be 
significantly associated with gene expression (p<0.044).  In addition, cell death (p<0.044) 
and cell morphology (p<0.044) were associated with 10 and 16 genes from the data set, 
respectively.  
 
 
4  Discussion 
 
In this study, we set out to compare the DNA methylation profiles of 16 Mexican 
individuals in the Hidalgo Region of Mexico.  The comparisons were between those 
individuals with signs of inorganic arsenic poisoning (e.g. skin lesions) versus those who did 
not have lesions.  The study site for this research was the city of Zimapan that was chosen as 
a study site because of its history as a region having arsenic-contaminated water from mining 
and other industries that occupied the area in the past.  The levels of inorganic arsenic in the 
drinking water in Zimapan range from 8-1,100 µg/l.  Approximately 2 million people reside 
A B 
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in this area. In the Zimapan region alone, more than 400,000 people drink water with 
inorganic arsenic levels higher than 25 ppb. A high prevalence of a skin disease typical of the 
chronic inorganic arsenic poisoning has been reported among the local residents.  
 
We classified 16 study subjects based on their known phenotypic classification of 
skin disease associated with arsenicosis. The initial analysis used a RRBS protocol focused 
on two subjects in the study population. Specifically, RRBS was used to identify the 
methylated CpG sites across the genomes of individual 15, who displayed signs of 
arsenicosis and control individual 13, who had no evidence of skin lesions.  The RRBS 
protocol identified 1.4 million common CpG sites between the two individuals. Close to 1 
million of these common sites fell into the CpG islands of 21,888 genes.  Average 
methylation was calculated across 21,888 CpG Islands for both samples.  The result was 
filtered for differences in average methylation between the control and exposed samples.  
From the 21,888 gene set, 791 genes showed a methylation change in the exposed sample 
that was a 4-fold or higher decrease in average methylation when compared to the control.  
About 321 genes displayed a four-fold or greater increase in average DNA methylation.  
These results show that a total of 1112 genes were differentially methylated in high-dose 
arsenic-exposed subject 15.   The genes that were differentially methylated were analyzed for 
significant molecular interactions. The results from our network analysis showed 6 
hypermethylated genes and 26 hypomethylated genes associated with the NF-κB pathway.   
It is interesting to find that the NF-kB pathway is enriched for differential methylation. NF-
kB is associated with cancer and has been shown to be a pathway that is dysregulated in 
humans exposed to inorganic arsenic (Fry et al., 2007). 
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 We next used MIRA to compare the DNA methylation in CpG islands across 14,363 
genes of 16 study subjects.  Methyl-enriched fragments isolated from each of 16 samples 
were mapped to 14,363 genes.  To examine differences in the population, the 16 samples 
were separated equally into two groups, an arsenicosis group and a healthy group.  The 
abundance of methylated fragments for the two groups was compared using statistical 
methods.  Next we used a heat map to compare differential methylation patterns. 
Interestingly, we observed that even at this level of analysis, which is unsupervised, there 
was a separation in the grouping of individuals with signs of arsenicosis.  
To establish molecular pathways that may be differentially methylated between 
individuals with signs of arsenicosis versus healthy individuals, we performed a network 
analysis on the gene set identified in the study. The gene set, which was obtained from a 
comparison of individuals with and without skin disease, was analyzed for molecular 
interactions.  Of our 183 significantly methylated genes loaded into the ingenuity database 
for network analyses, 125 mapped to significant interactomes or interacting protein networks.  
Of 125 genes, 11 (9%) of these genes were significantly associated with cancer.  Of the 
cancer-associated genes identified, 5 were enriched for tumorigenesis (p<0.0296) and 5 were 
enriched for transformation (p<0.0401).  These findings are important because members of 
the arsenicosis study group had signs of basal cell carcinoma and squamous cell carcinoma, 
which has been shown to be caused by arsenic poisoning.   Furthermore, many types of 
cancer are associated with arsenic exposure, including skin, liver, and kidney cancer.  The 
differentially methylated genes in our arsinocosis group were also associated with other 
arsenicosis-related diseases, such as cardiovascular disease (p<0.044) and gastrointestinal 
disease (p<0.0296).    Top associations of the gene set with molecular and cellular functions 
 19 
 
were also analyzed.  As many as 26 genes (20%) of the 126 mapped genes were found to be 
significantly associated with gene expression (p<0.044).  Cell death (p<0.044) and cell 
morphology (p<0.044) were associated with 10 and 16 molecules from the data set, 
respectively.  
From the network analysis, we also discovered that the top network of significant 
interacting genes generated by Ingenuity included 21 hypermethylated genes from our gene 
set that were associated with the NF-κB pathway.  The network analysis showed that the 
diseases and functions associated with this top network of genes were genetic disorder, 
metabolic disease, and digestive system development and function.  Three genes in our 
network that interact directly with NF-κB are Forhead box F1 (FOXF1), TSC22 domain 
family, member 3 (TSC22D3), and ubiquitin-conjugating enzyme E2E2 (UBE2E2).  FOXF1 
and TSC22D3 were identified as transcriptional regulators in our analysis.   These genes are 
associated with apoptosis and cancer.  Recently, there has been evidence to show that the 
FOXF1 gene is targeted for epigenetic inactivation in breast cancer cell lines and functions 
normally as a tumor-suppressor gene (Lo et al., 2010).   Experiments were carried out to 
show that restoration of FOXF1 functioning in vitro, through removing methylation using 5’-
aza-2’-deoxycytidine, leads to G1arrest in the cell cycle, thereby suppressing in vitro cell 
growth and tumor growth (Lo et al., 2010).  Through this finding, it is suggested that 
hypermethylation of FOXF1 causes its suppression and can lead to cancer.   TSC22 is a class 
of genes that are methylated or silenced in many tumors.  Yu and colleagues found that 
TSC22 is a tumor suppressor gene (Yu et al., 2009).  They showed this through 
demethylation of this gene, which reversed its deregulation in T and NK LGL leukemia, 
leading to increased survival of mice with the disease (Yu, et al., 2009).  Expression of the 
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gene in mouse leukemia or lymphoma cell lines concluded in slower in vivo tumor growth.  
UBE2E2 is a tumor suppressor gene that has been used as a biomarker to detect the 
squamous cell carcinoma (Haraldson, 2010).  Methylated or silenced UBE2E2 is detected 
using NotI microarrays, which detects hypermethylated cancer-associated genes. 
 In addition, there were 14 hypermethylated genes that were associated with p53, of 
which the top associated biological function was cellular growth and proliferation.  In the 
p53 network, 4 of the 14 genes depicted in the network analysis as hypermethylated or 
silenced, included G-2 and S-phase expressed 1 (GTSE1), eukaryotic translation elongation 
factor 1 epsilon 1 (EEF1E1), and Siva1.  GTSE1 has a p53 binding site in its promoter region 
and is transcriptionally activated by p53.  This gene has been found to negatively regulate 
p53’s protein levels, transactivation, and apoptosis.  Recent work suggests a physiological 
role for this gene increasing sensitivity of cells to DNA damage-induced apoptosis (Monte et 
al., 2003).  EEF1E1 is a tumor suppressor gene that upregulates p53 by activating cell repair 
machinery in DNA damage repair processes.  This gene plays vital part in preventing cellular 
transformation.  Studies have shown that mice, which possess the genotype EEF1E1 +/-, 
have higher rates of tumor development than wild-type mice (Kim et al., 2008).  It was 
discovered that this gene was not silenced by mutations in these mice, but by another 
mechanism, possibly hypermethylation (Kim et al., 2008).  Siva1 is suggested to be a 
proapoptotic protein that interacts and suppresses a potent inhibitor of apoptosis, X 
chromosome-linked inhibitor of apoptosis (XIAP) (Du et al., 2009).  SIVA1 inhibits XIAP-, 
TAKI-TABI-mediated activation of NKκB, but increases c-JUN NH2-terminal protein 
kinase, (JNK) activity to increase apoptosis (Du et al., 2009).  Furthermore, Siva1 has been 
suggested to strongly inhibit p53 activity as a non-lethal stress response, but during major 
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DNA damage, interactions between Siva1 and p53 reduces to allow upregulation of p53 to 
prevent tumor formation. (Du et al. 2009).  KNTC1 (kinetochore associated protein 1) helps 
to ensure that chromosomes segregate properly during cell division (Naqvi et al., 2009).  The 
fact that this gene is one of the hypermethylated genes identified in one of our networks 
suggests that its silencing may play a part in transformation of arsenic exposed cells that can 
lead to skin disease and cancer development. 
It is interesting to observe that p53 and NF-κB are enriched as the 1st and 2nd most 
significant networks of interacting proteins of 22 significant networks.   As mentioned 
previously, p53 has been shown to be differentially methylated in humans exposed to arsenic.  
In a study conducted in an arsenic-endemic area in India, molecular analysis on DNA 
extracted from peripheral whole blood showed that the promoter region of the p53 gene was 
significantly hypermethylated in individuals who were chronically exposed to high doses of 
arsenic and had skin lesions (Chanda et al., 2006).   Therefore, it is not surprising to find that 
genes associated with p53 are also hypermethyated in arsenic exposed individuals showing 
signs of arsenicosis.   
Many of the genes identified in the NF-κB network are involved in apoptosis, 
differentiation, and cell growth.  These genes, which are involved in apoptosis, may be 
silenced in individuals with arsenicosis, giving room for transformation of normal cells into 
cancerous cells.  Apoptosis is a process known to prevent abnormal cells from dividing and 
proliferating and therefore the silencing of many genes that are involved in apoptosis may 
contribute to tumor progression and eventually cancer, which can be found in individuals 
who are exposed to high-dose arsenic and show signs of arsenicosis.  Our network analysis 
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identifies methylation of p53-and NF-κB associated genes and, therefore, may indicate how 
arsenic exposure affects humans at a molecular level and can lead to skin disease or cancer.    
 
5  Conclusions 
In this study, we identified genes that are differentially methylated and associated 
with arsenic exposure and disease in a human cohort from Mexico. To our knowledge, these 
data represent the first genome-wide scan for alterations in the epigenetic profiles of arsenic-
exposed humans. We show that there are a large number of genes that are differentially 
methylated between individuals with skin disease and those without skin disease.When these 
genes are analyzed for molecular pathway association, we observed enrichment for the NF-
κB pathway, P53, and associated genes.  As NF-κB is known to be involved in tumor 
progression and P53 is a tumor suppressor gene that once silenced has been known to lead to 
skin cancer, these results are very interesting.  We conclude that our findings suggest that 
DNA methylation changes may be a key biological connection between arsenic exposure and 
arsenic-induced disease.   
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6  Future Directions 
Our findings suggest that differential methylation of genes affiliated with the NF-κB 
and P53 pathways are associated with arsenicosis.  In future studies, we desire to confirm 
methylation of DNA targets in the arsenicosis group by using real-time PCR to investigate 
expression levels of genes identified in our networks as differentially modulated.  We expect 
that methylated genes in arsenicosis subjects would be silenced and, therefore, show little or 
no expression in comparison to healthy subjects.  We also plan to look at the urinary profiles 
of arsenic metabolites for each study participant and match these profiles to DNA 
methylation patterns and skin disease manifestations.  Comparing these parameters will allow 
us to look for patterns between arsenic exposure and the molecular basis for arsenic-induced 
disease. 
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